Search

everythinglearnresearchcommunity

for

Search:↓

The 2006 editorial concluded that immunotherapy was advancing with new drugs, focusing on specific biological therapies and convenient oral treatments, and highlighted the importance of partnerships and new regulations in the field.

Diphencyprone is effective for treating patchy hair loss in alopecia areata, but tacrolimus is not.

Tumor immunotherapy can cause hair loss by disrupting hair follicle immunity.

Some patients with severe alopecia areata developed skin darkening from their treatment, which may indicate a less effective response to the therapy.

Eculizumab helps reduce blood transfusions and stabilize hemoglobin but increases infection risk and is expensive.

Tofacitinib works better and is more tolerable for severe alopecia than conventional treatments and DPCP immunotherapy.

Cutaneous ultrasound is a useful tool for diagnosing and assessing inflammation in tinea capitis.

Research on HIV-1 capsid inhibitors has progressed significantly, with the U.S. leading in contributions.

The new microneedle patch effectively treats alopecia areata with fewer side effects than oral medication.

The study found that a key immune pathway protecting hair follicles is reduced in a mouse model of scarring hair loss.

Immunotherapies for non-small cell lung cancer show promise in improving treatment and reducing side effects.

Some cases of tinea capitis, a fungal scalp infection, can look like scarring hair loss due to the body's immune response and the fungus itself.

The InvisiCaps Method ensures natural-looking hair extensions by carefully matching donor hair characteristics.

New micelle nanocarriers deliver Tacrolimus more effectively to skin layers for psoriasis treatment than the current Protopic ointment.

Follicular dystrophy in immunocompromised patients may be linked to medication or viral factors and can improve with treatment changes.

Capilcep effectively promotes hair growth and is safe, but long-term effects need more research.

UTMD with diclofenac and Doxil® improves cancer treatment by boosting immune response and reducing tumor-supporting cells.

The treatment was effective for advanced non-Hodgkin's lymphomas.

Ivarmacitinib significantly improved hair regrowth in severe alopecia areata after tofacitinib was less effective.

Anti-PD-L1 immunotherapy can cause hair loss and unexpected hair color change, but treatment can restore hair growth and color.

Diphenylcyclopropenone topical immunotherapy is effective for treating alopecia areata, with some side effects.

Superficial cryotherapy significantly improves eyebrow hair growth in alopecia universalis patients.

Pimecrolimus boosts melanin production and movement of skin pigment cells.

2h-ICPR can help screen for insulin antibodies in type 2 diabetes patients.

Machine learning can help find new ways to treat alopecia areata.

Immunochemotherapy successfully treated neutropenia in a patient with Waldenström's macroglobulinemia.

Topical immunotherapy is still effective for managing alopecia areata, even with new treatments available.

Blocking CD44 can reduce leukocyte migration in autoimmune skin diseases.